ClinicalTrials.gg
CompletedNCT06118255ORCHIDUpdated Sep 17, 2026

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome

A Phase 3 interventional study of fenfluramine in Dravet Syndrome, sponsored by UCB BIOSCIENCES, Inc.. Completed at 12 sites in 5 countries. Open to participants aged 1 Year to 23 Months. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by UCB BIOSCIENCES, Inc. (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
1 Year to 23 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing fenfluramine in Epilepsies, Myoclonic — 2 open to participants now, 2 under way, none of them phase 3. Fenfluramine · Epilepsies, Myoclonic.

Enrollment
6th of 11
25 · median 25
Started
2024
with 1 other
Phase 3
7 of 11
none open now
Registered
9th of 11
by date
Lead sponsor
1 of 11
UCB BIOSCIENCES, Inc.

Among the 11 studies testing fenfluramine in Epilepsies, Myoclonic, this one is the 6th largest by enrollment, is one of 2 that started in 2024, is one of 7 in phase 3, and was the 9th registered.

Epilepsies, Myoclonic

92 studies on the registry are indexed under Epilepsies, Myoclonic; 21 are open to participants now.

Browse Epilepsies, Myoclonic studies →

Open to participants now

2 of the 11 studies testing fenfluramine in Epilepsies, Myoclonic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fenfluramine

Fenfluramine: first FDA approval 2020 (FINTEPLA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Epilepsies, Myoclonic studies recruiting now, 3 (21%) set no upper age limit and 10 (71%) stop at 75 or younger; 11 take children under 18; 3 take healthy volunteers.

This study: 1 Year to 23 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing fenfluramine in Epilepsies, Myoclonic, or all of them as a file.
02

Study summary

The primary purpose of this study is evaluate the safety and tolerability of fenfluramine hydrochloride (HCl) 0.2 to 0.8 mg/kg/day in infants 1 year to less than 2 years of age with Dravet syndrome.

03

Conditions studied

  • Dravet Syndrome

Browse trials for

Keywords

  • Dravet syndrome
  • pediatrics
  • Fintepla
  • fenfluramine
04

Who can participate

Ages eligible
1 Year to 23 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is ≥1 to \<2 years of age as of the day of the first administration of study drug
  • Participant has a documented diagnosis or likely diagnosis of Dravet syndrome according to the International League Against Epilepsy (ILAE) criteria and as agreed by the Epilepsy Study Consortium (ESC)
  • Participant must be currently receiving ≥1 concomitant anti seizure medication (ASM) at a stable dose for ≥4 weeks prior to the Screening Visit and is expected to remain stable throughout the study. Rescue medications for seizures are not counted towards the total number of ASMs
  • Participant must have drug resistant epilepsy as defined as a history of failure of adequate trials of 2 tolerated, appropriately chosen and used antiepileptic drug schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom
  • Participants must have ≥1 countable motor seizures (CMS) during the Baseline Period. The CMS include distinct seizures of generalized tonic-clonic, bilateral clonic, focal motor, bilateral tonic, atonic (drop), bilateral tonic/atonic, or focal to bilateral tonic-clonic type. If the participant fails to have ≥1 qualifying seizures in 28 days, the Baseline Period may be extended by an additional 14 days with Sponsor approval. Participants with an extended Baseline Period must still have ≥1 CMS in the 28 days immediately prior to the day of the first administration of study drug
  • Body weight is ≥8 kg
  • Males and females

Exclusion criteria

Exclusion Criteria:

  • Participant has a known to fenfluramine hydrochloride (HCl) or any of the in the study drug
  • Participant has an exclusionary cardiovascular or cardiopulmonary abnormality based on echocardiogram (ECHO), (ECG), or physical examination and is not approved for entry by the central cardiac reader
  • Participant has a diagnosis of pulmonary arterial hypertension
  • Participant has a medical condition, including , interstitial lung disease, or portal hypertension, or has had clinically relevant symptoms or a clinically significant illness currently or in the 4 weeks prior to the Screening Visit, other than epilepsy, that in the opinion of the Investigator would negatively impact study participation, collection of study data, or pose a risk to the participant
  • Participant has current or past history of cardiovascular or cerebrovascular disease, such as cardiac valvulopathy, myocardial infarction or stroke, severe ventricular arrhythmias, or clinically significant structural cardiac abnormality, including but not limited to mitral valve prolapse, atrial or ventricular septal defects, patent ductus arteriosus, and patent foramen ovale with reversal of shunt. (Note: Patent foramen ovale or a bicuspid aortic valve are not considered exclusionary.)
  • Participant has a current or past history of glaucoma
  • Participant has moderate to severe hepatic impairment, assessed based on the classification system
  • Participant has moderate to severe renal impairment (estimated \<50 mL/min/1.73 m\^2 calculated with the updated Bedside Schwartz equation for children
  • corrected (QTc) >450 msec
  • Participant is taking >4 concomitant ASMs
  • Participant is receiving concomitant treatment with cannabidiol other than Epidiolex/Epidyolex or is being actively treated with tetrahydrocannabinol (THC) or any marijuana product for any condition
  • Participant is receiving concomitant therapy with any of the following: centrally-acting anorectic agents; monoamine-oxidase inhibitors; any centrally-acting compound with clinically appreciable amount of serotonin agonist or antagonist properties, including serotonin reuptake inhibition; other centrally-acting noradrenergic agonists, including atomoxetine; or cyproheptadine. Disallowed medications are subject to washout of ≥5 half-lives before the first day of study drug administration
  • Participant is currently receiving another product(s) or has received another investigational product within 30 days or within \<5 times the half-life of that investigational product, whichever is longer, prior to the Screening Visit
  • Participant has previously been treated with Fintepla (fenfluramine HCl) prior to the Screening Visit
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Fenfluramine Open-label

    All study participants will initiate fenfluramine hydrochloride (HCl) treatment at 0.2 mg/kg/day in the Dose-Finding Period and may be up-titrated to a maximum of 0.8 mg/kg/day based on the Investigators discretion. The dose of fenfluramine HCl can be flexibly titrated during the Maintenance Period. Study participants, who discontinue early will participate in the Taper Period. All participants will complete an End of Treatment (EOT) Visit.

    Drug: fenfluramine

Interventions

  • The study drug, fenfluramine HCl, is an oral solution to be administered in equal doses twice daily (BID). It will be based on the current dose and participant's weight (kg).

    Also known as: Fintepla

06

What researchers measure

Primary outcomes

  1. Change from Baseline in QT interval corrected by Fridericia (QTcF) at Visit 13 (End of Treatment/Early Termination (EOT/ET))

    QTcF is the QT interval corrected for heart rate according to Fridericia's formula. Higher values correspond to prolongation of QT interval.

    Time frame: Week 52 (Visit 13; EOT/ET), compared to Baseline

  2. Occurrence of a treatment-emergent (ie, post-Baseline through Visit 13 [EOT/ET]) result which meets the FDA case definition of drug associated valvulopathy

    Drug associated valvulopathy refers to aortic regurgitation with severity mild or greater and/or mitral regurgitation with severity moderate or greater.

    Time frame: From post-Baseline (Day 1) through Visit 13 (EOT/ET) (up to 52 weeks)

  3. Occurrence of treatment-emergent (ie, post-Baseline through Visit 13 [EOT/ET]) clinically confirmed valvular heart disease (VHD)

    Clinically confirmed VHD is an aortic regurgitation with mild or greater severity and/or a mitral regurgitation with moderate or greater severity.

    Time frame: From post-Baseline (Day 1) through Visit 13 (EOT/ET) (up to 52 weeks)

  4. Change from Baseline in body weight (Z-score) at each visit

    Body weight (Z-score) refers to the number of standard deviations a participant's body weight lies from the mean, when compared to others of similar gender and age.

    Time frame: Week 1 (Visit 3), Week 4 (Visit 5), Week 8 (Visit 7), Week 12 (Visit 8), Week 16 (Visit 9), Week 20 (Visit 10), Week 26 (Visit 11), Week 39 (Visit 12), Week 52 (Visit 13), Postdose Safety Follow-Up (Visit 14), compared to Baseline

  5. Change from Baseline in recumbent length (Z-score) at each visit

    Recumbent length (Z-score) refers to the number of standard deviations a participant's body weight lies from the mean, when compared to others of similar gender and age.

    Time frame: Week 1 (Visit 3), Week 4 (Visit 5), Week 8 (Visit 7), Week 12 (Visit 8), Week 16 (Visit 9), Week 20 (Visit 10), Week 26 (Visit 11), Week 39 (Visit 12), Week 52 (Visit 13), Postdose Safety Follow-Up (Visit 14), compared to Baseline

  6. Occurrence of a clinically significant abnormality on the neurological examination at each visit

    A complete neurological examination will be conducted by the investigator for each participant covering cranial nerves, muscle strength and tone, reflexes, coordination, sensory function, and gait.

    Time frame: Week 1 (Visit 3), Week 4 (Visit 5), Week 8 (Visit 7), Week 12 (Visit 8), Week 16 (Visit 9), Week 20 (Visit 10), Week 26 (Visit 11), Week 39 (Visit 12), Week 52 (Visit 13), Postdose Safety Follow-Up (Visit 14), compared to Baseline

Secondary outcomes

  1. Percentage change from the Baseline Period (ie, Baseline) in monthly (28 days) countable motor seizure frequency (CMSF), during Weeks 9 through 20

    The percentage change from the Baseline Period (Baseline) in "monthly (28 days) countable motor seizure frequency," or CMSF, during Weeks 9 through 20

    Time frame: During Weeks 9 to 20, compared to Baseline

  2. Percentage change from Baseline in CMSF during Weeks 1 through 20

    The percentage change from the Baseline Period (Baseline) in "monthly (28 days) countable motor seizure frequency," or CMSF, during Weeks 1 through 20

    Time frame: During Weeks 1 to 20, compared to Baseline

  3. Percentage change from Baseline in CMSF during the Treatment Period (Week 1 through the EOT/ET Visit)

    The percentage change from the Baseline Period (Baseline) in "monthly (28 days) countable motor seizure frequency," or CMSF, during the Treatment Period (Week 1 through the EOT/ET Visit; up to 52 weeks)

    Time frame: During the Treatment Period (Week 1 through EOT/ET) (up to 52 weeks), compared to Baseline

  4. Achievement of a Clinical Global Impression - Improvement (CGI-I) rating of "much improved" or "very much improved" as assessed by the Principal Investigator at Week 20

    The CGI-I rating scale permits a global evaluation of the participant's improvement over time by the investigator on a 7-point scale.

    Time frame: At Week 20

  5. Achievement of a CGI-I rating of "much improved" or "very much improved" as assessed by the parent/caregiver at Week 20

    The CGI-I rating scale permits a global evaluation of the participant's improvement over time by the parent/caregiver on a 7-point scale.

    Time frame: At Week 20

  6. Steady-state maximum plasma concentration (Cmax) of fenfluramine and norfenfluramine at Week 12

    Mean peak (maximum) plasma concentration of fenfluramine and norfenfluramine will be reported at Study Week 12 when participants are in the Maintenance Period.

    Time frame: At Week 12

  7. Steady-state minimum plasma concentration (Cmin) of fenfluramine and norfenfluramine at Week 12

    Mean minimum plasma concentration of fenfluramine and norfenfluramine will be reported at Study Week 12 when participants are in the Maintenance Period.

    Time frame: At Week 12

  8. Area under the plasma concentration time curve from time zero to 24 hours (AUC0 24) for steady-state fenfluramine and norfenfluramine at Week 12

    Mean AUC0-24 values of fenfluramine and norfenfluramine will be reported at Study Week 12 when participants are in the Maintenance Period.

    Time frame: At Week 12

07

Study locations

12 sites
  • Ep0213 105
    Memphis, Tennessee 38103-2800, United States
  • Ep0213 107
    Dallas, Texas 75207, United States
  • Ep0213 103
    Seattle, Washington 98105, United States
  • Ep0213 502
    Brussels, Belgium
  • Ep0213 501
    Edegem, Belgium
  • Ep0213 303
    Bielefeld, Germany
  • Ep0213 202
    Florence, Italy
  • Ep0213 203
    Genova, Italy
  • Ep0213 201
    Roma, Italy
  • Ep0213 204
    Roma, Italy
  • Ep0213 403
    Glasgow, United Kingdom
  • Ep0213 401
    London, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if a determination is made that the data cannot be adequately anonymized.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Sep 2026, 27 months.

Of 15 phase 3 interventional studies under Epilepsies, Myoclonic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 72. This study's 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2023
First posted
Nov 7, 2023
StartActual
May 21, 2024
Primary completionActual
Sep 1, 2026
CompletionActual
Sep 1, 2026
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06118255
Responsible party
Sponsor
First posted
Nov 7, 2023
Start date
May 21, 2024
Primary completion
Sep 1, 2026
Completion
Sep 1, 2026
Last update
Sep 17, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fenfluramine

Start the discussion